| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | Biotron is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1, and a promising preclinical program for HBV. In addition, Biotron has several earlier stage programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses. |
| Category: | Health & biotech |
| URL: | https://www.biotron.com.au/ |
| Operational Status: | |
| ASX Listing Code (if applicable): | |
| Year of Commencement: | |
| Address: | 56 Delhi Rd, North Ryde, New South Wales 2113, AU |
| State: | New South Wales |
| Overseas Operations: | |
| X: | |
| Facebook: | |
| Linkedin: | https://linkedin.com/company/biotron-ltd |
| Founders: |
No items found
|
| Awards won: | |
